Overview
RLMD market data
Price History
RLMD price chart · 1M
- O
- 4.51
- H
- 4.58
- L
- 4.49
- C
- 4.55
- Vol
- 31,751.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $4.51
- Previous Close
- $4.54
- Day High
- $4.58
- Day Low
- $4.49
- 52 Week High
- $7.99
- 52 Week Low
- $4.36
- 7 Day Return
- -2.26%
- 30 Day Return
- -13.17%
- 90 Day Return
- -36.98%
- 1 Year Return
- -38.22%
- Daily Notional Volume
- $144.5K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.45 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.49 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -500.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.60 – $8.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $508.3M · P/B 4.09.
Company News
8-K filing — RELMADA THERAPEUTICS, INC. (RLMD)SEC EDGAR · Aug 6, 2026, 8:40 PM
Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) EstimateBenzinga · Aug 6, 2026, 8:10 PM
Relmada Therapeutics Joins Russell 2000® and Russell 3000® IndexesGlobenewswire Inc · Jun 29, 2026, 11:15 AM
Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 IndexBenzinga · Jun 29, 2026, 11:15 AM
Relmada's Cancer Drug Candidate Sparks Fresh Bullish CallBenzinga · Jun 18, 2026, 5:45 PM
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jun 18, 2026, 11:50 AM
Hewlett Packard Enterprise Posts Blowout Q2 Earnings, Joins Marvell Technology And Other Big Stocks Moving Higher In Tuesday's SessionBenzinga · Jun 2, 2026, 12:20 PM
Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder ApprovalBenzinga · May 28, 2026, 9:24 PM